ECCO 2022
Combination trials open a new door in IBD treatment
Abstract: OP36
high5immunology.tv | IBD | ECCO 2022
VEGA
ECCO 2022
Combination trials open a new door in IBD treatment
SELECTION, GALAXI 1, LUCENT-1
ECCO 2022
Combined endpoints as new therapy goals
SERENITY
ECCO 2022
The potential of histology in Crohn´s disease and how…
RESTORE-UC
ECCO 2022
Microbiota manipulation: Still a lot to learn
EARNEST, DIVERGENCE 2
ECCO 2022
Light at the end of the Pouchitis track
SPARE
ECCO 2022
Is the continuation of combination therapy the key to…
ECCO 2022
The interleukin-17 conundrum
SPARE
ECCO 2022
Withdrawal of infliximab or anti-metabolite therapy in…
SPARE
ECCO 2022
When to withdraw therapy in crohn's disease?
VEGA
ECCO 2022
Combination of biologics - finally arrived in IBD!?
VEGA
ECCO 2022
Combination with different classes of drugs in moderate…
NOR-DRUM B
ECCO 2022
Proactive TDM or SOC for monitoring infliximab…
SPARE
ECCO 2022
SPARE study in ECCO 2022
SPARE
ECCO 2022
Infliximab withdrawl leeds to a higher risk of…
ECCO 2022
Is the speedity of the steroid tapering important…
SPARE
ECCO 2022
How to deescalate treatment in CD?
VEGA
ECCO 2022
Combination of biologics
SEAVUE / STARDUST
ECCO 2022
Ustekinumab for fistulizing disease
RESTORE-UC
ECCO 2022
FMT is not a promising option for UC patients
VEGA
ECCO 2022
Will we improve the management of IBD by combining…
RESTORE-UC
ECCO 2022
FMT in UC - still far away from the success story
DIVERGENCE 2
ECCO 2022
Filgotinib for fistulizing disease
SPARE
ECCO 2022
Is stopping of therapy an option in CD?
RESTORE-UC
ECCO 2022
A negative control trial for FMT in UC
VEGA
ECCO 2022
The first combination therapy trial
NOR-DRUM B
ECCO 2022
Proactive TDM
NOR-DRUM B
ECCO 2022
A new opportunity for proactive TDM disease control
SPARE
ECCO 2022
Du nouveau sur l’allégement thérapeutique au cours de…
ECCO 2022
Das Interleukin-17 Rätsel
SPARE
ECCO 2022
Wann Beendigung von Infliximab oder Immunmodulatoren…
NOR-DRUM B
ECCO 2022
Una nuova opportunità per i TDM nel controllo proattivo…
SPARE
ECCO 2022
Ist der Therapiestopp eine Option in CD?
VEGA
ECCO 2022
Allons nous améliorer la prise en charge des MICI en…
SPARE
ECCO 2022
מחקר SPARE ב ECCO 2022
NOR-DRUM B
ECCO 2022
Προληπτική μέτρηση των θεραπευτικών επιπέδων του…
ECCO 2022
Επηρεάζει η ταχύτητα διακοπής των κορτικοστεροειδών την…
RESTORE-UC
ECCO 2022
FMT ist kein vielversprechender Ansatz für UC-Patienten
RESTORE-UC
ECCO 2022
Un essai négatif sur la transplantation de microbiote…
VEGA
ECCO 2022
Combinazione di biologici
VEGA
ECCO 2022
Il primo trial di terapia biologica di combinazione
VEGA
ECCO 2022
Kombination von Biologika - endlich bei IBD…
RESTORE-UC
ECCO 2022
FMT w colitis ulcerosa - wciąż daleko od sukcesu
VEGA
ECCO 2022
Is combination therapy safe?
OCTAVE / RIVETING, DIVERGENCE 2, U-ACHIEVE
ECCO 2022
Can we translate rheumatoid arthritis to ulcerative…
ECCO 2022
Inflammatory bowel disease and cancer risk
CLARITY IBD
Ecco 2022
COVID-19: still a moving target!
ECCO 2022
Which IBD patients have a higher risk of safety…
ECCO 2022
The heart is apparently safe with continuous Ozanimod…
VEGA
ECCO 2022
A touch of the near future in IBD treatment
MECONIUM
ECCO 2022
Breastmilk is tuning IBD risk
MECONIUM
ECCO 2022
Muttermilch beeinflusst das IBD-Risiko
ECCO 2022
Il cuore sembra essere apparentemente al sicuro durante…
VEGA
ECCO 2022
Uno sguardo al prossimo futuro nel trattamento delle…
SEAVUE / STARDUST, DIVERGENCE 2
ECCO 2022
Fistulizing Crohn‘s disease - new treatment options…
VEGA, GALAXI 1, QUASAR, LUCENT-1
ECCO 2022
The race is on IL-23 – exciting data for CD and UC
U-ACHIEVE / U-ACCOMPLISH, SELECTION
ECCO 2022
Efficacy update on JAKis
ECCO 2022
Mucosal healing: Will efficacy data translate into real…
EARNEST, VEDOKIDS, VEDOIBD
ECCO 2022
Vedolizumab: promising data for pouchitis and IBD in…
EARNEST
ECCO 2022
Great news on pouchitis treatment - vedolizumab…
EARNEST
ECCO 2022
New opportunity in pouchitis treatment
ECCO 2022
New ways of treatment
ECCO 2022
Upadacitinib - will it be the game changer in UC?
GALAXI 1
ECCO 2022
Guselkumab as maintenace treatment in Crohn's Disease
EARNEST
ECCO 2022
Vedolizumab is effective in chronic pouchitis after…
U-ACHIEVE / U-ACCOMPLISH, SELECTION / SELECTIONLTE, DIVERGENCE 2, OCTAVE / RIVETING
ECCO 2022
JAK inhibition
QUASAR, GALAXI 1, LUCENT-1, FORTIFY
ECCO 2022
Anti-IL-23 - a turning point?
EARNEST
ECCO 2022
Vedolizumab in chronic pouchitis - a new chapter in…
QUASAR, GALAXI 1, LUCENT-1, FORTIFY
ECCO 2022
Selective IL-23 blockade
U-ACHIEVE / U-ACCOMPLISH, SELECTION / SELECTIONLTE, DIVERGENCE 2, OCTAVE / RIVETING
ECCO 2022
JAK-Inhibition
QUASAR, GALAXI 1, LUCENT-1, FORTIFY
ECCO 2022
Selektive IL-23 Blockade
ECCO 2022
Upadacitinib - nowy lek, duże nadzieje
ECCO 2022
Nuevos caminos en el tratamiento
QUASAR, GALAXI 1, LUCENT-1, FORTIFY
ECCO 2022
Anti-IL-23 - eine Zeitenwende?
EARNEST
ECCO 2022
Wedolizumab w pouchitis - początek nowego rozdziału w…
EARNEST
ECCO 2022
Una nuova opportunità nel trattamemto della pouchite
GALAXI 1
ECCO 2022
Guselkumab come terapia di mantenimento
U-ACHIEVE
ECCO 2022
Patient relevant outcomes also show efficacy of…
LUCENT-1 and others
ECCO 2022
New therapy goals: urgency and disease clearance
SELECTION
ECCO 2022
New therapeutic goals in UC
SELECTION
ECCO 2022
Disease control is possible!
SERENITY
ECCO 2022
Histological findings in mirikizumab treatment
EPIMAD registry
ECCO 2022
Natural history of anal ulcerations in pediatric-onset…
ECCO 2022
New goals for IBD
EPIMAD registry
ECCO 2022
Histoire naturelle de la maladie de Crohn ano-périnéale…
ECCO 2022
Nuevas objetivos en las EII
SELECTION
ECCO 2022
Disease Control ist möglich!
LUCENT-1 and others
ECCO 2022
Urgency und Disease Clearance
VIP, CLARITY IBD
ECCO 2022
The efficacy of COVID-19 vaccines in IBD - what's new?
VIP, RECOVERI
ECCO 2022
COVID-19 in patients with IBD stratified acc. to…
VIP, RECOVERI
ECCO 2022
תגובה חיסונית לחיסונים כנגד קורונה בחולים עם מחלות מעי…
VIP, CLARITY IBD
ECCO 2022
Skuteczność szczepień przeciw COVID-19 w IBD - nowe…
ECCO 2022
Point of Care Testing / AI / Telemedicine
TRUST BEYOND
ECCO 2022
Ultrasound as a predictor of treatment response
TRUST BEYOND
ECCO 2022
Ultraschall als Prädiktor des Therapieansprechens
ECCO 2022
Digitale Tools, KI und Telemedizin
ECCO 2022
ECCO guidelines on pregnancy
EITOS, VERSUS-CD, DUMBO
ECCO 2022
Spanish women leading contribution to ECCO 2022
EITOS, VERSUS-CD, DUMBO
ECCO 2022
Las mujeres lideran la contribución española a la ECCO…
ECCO 2022
ECCO Richtlijnen zwangerschap
Für den erfolgreichen Abschluss der Fortbildungsmodule ist die korrekte (mind. 70%) Beantwortung der Lernerfolgskontrolle für das jeweilige Modul verpflichtend.
Jetzt gleich den Fragebogen ausfüllen!